drugset
drugset / Trial / NCT06516952

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952 ↗

Phase 3 Active not recruiting 349 enrolled Incyte Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Timeline

Start
2024-10-10
Primary completion
2026-10-19
Completion
2027-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule — Oral

Indications

prurigo nodularis